In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.

Cancer Cell Int · 2023 · PMC9909954 · PMID 36759818

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

P < 0.05 was considered to indicate a significant difference, P < 0.01 was considered to indicate a highly significant difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.